



# **Assessment of Vitamin D Level in Newly Diagnosed Multiple Myeloma Patients and Patients in Remission**

*Thesis*

*Submitted for Partial Fulfillment  
of Master Degree in Internal Medicine*

*By*

***Mostafa Mahmoud Fouad Mahmoud***  
*M.B.B.CH*

*Under Supervision of*

**Prof. Dr. / Shaza Abd El Wahab El Kourshy**

*Professor of Internal Medicine and Clinical Hematology  
Faculty of Medicine - Ain Shams University*

**Assist. Prof. / Hanaa Fathey Abd El Samee**

*Assistant Professor of Internal Medicine and Clinical Hematology  
Faculty of Medicine - Ain Shams University*

**Dr. / Nahed Moawad Ibrahim**

*Lecturer of Internal Medicine and Clinical Hematology  
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine - Ain Shams University**

**2019**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

## Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. / Shaza Abd El Wahab El Kourshy**, Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Assist. Prof. / Hanana Fathey Abd El Samee**, Assistant Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr. / Mahed Moawad Ibrahim**, Lecturer of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, for her great help, outstanding support, active participation and guidance.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

**Mostafa Mahmoud Fouad Mahmoud**

# List of Contents

Title	Page No.
List of Tables .....	5
List of Figures .....	7
Introduction.....	- 1 -
Aim of the Work .....	14
Review of Literature	
▪ Multiple Myeloma.....	15
▪ Vitamin D.....	52
▪ Vitamin D in Haematological Disorders and Malignancies:.....	60
Patients and Methods .....	64
Results .....	68
Discussion.....	82
Summary .....	86
Conclusion .....	88
Recommendations .....	89
References .....	90
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table 1:</b>	In 2014, the International Myeloma Working Group (IMWG) updated the diagnostic criteria for MM and Plasma Cell related disorders .....	19
<b>Table 2:</b>	Dermatological manifestations .....	26
<b>Table 3:</b>	Durie-Salmon Staging System.....	27
<b>Table 4:</b>	The International Staging System (ISS).....	28
<b>Table 5:</b>	The Revised-International Staging System (R-ISS).....	28
<b>Table 6:</b>	The Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) .....	29
<b>Table 7:</b>	Cytogenetic Abnormalities on Clinical Course and Prognosis in Multiple Myeloma:.....	30
<b>Table 8:</b>	Selected Drugs with significant single-agent activity in multiple myeloma:.....	34
<b>Table 9:</b>	Selected Drugs with activity in combination with other active agents in multiple myeloma:.....	35
<b>Table 10:</b>	International Myeloma Working Group uniform response criteria for multiple myeloma.....	44
<b>Table 11:</b>	Vitamin D prevalence among the general population compared to multiple myeloma patients .....	62
<b>Table 12:</b>	Comparison between the three groups regarding sex and age .....	68

## List of Tables *cont...*

Table No.	Title	Page No.
<b>Table 13:</b>	Comparison between post therapy group and newly diagnosed group regarding B.M, Ca, LDH, B2 micro, Creat., Bone lesions, Hb, Stage .....	69
<b>Table 14:</b>	Comparison between the three groups regarding vitamin D level .....	72
<b>Table 15:</b>	Comparison between post therapy group and newly diagnosed group regarding vitamin D level .....	74
<b>Table 16:</b>	Comparison between the Insufficient group and Sufficient group regarding Age, Sex, B2 micro, LDH, Creat., Ca, Bone lesions, Hb, Stage, B.M .....	75
<b>Table 17:</b>	Correlation between vitamin D level regarding Age, B.M, B2 micro, CD138 .....	76
<b>Table 18:</b>	Correlation between sex, LDH, createnine, bone lytic lesions, hemoglobin, stage and vitamin D level. ....	77
<b>Table 19:</b>	Comparison between the deficient group, insufficient group and sufficient group regarding age, sex, B2 micro, LDH, creat., ca, bone lesions, Hb, stage, B.M .....	78
<b>Table 20:</b>	Correlation between vitamin D level and age, B2 microglobulin, CD138 expression and percentage of Plasma cells in B.M.....	79
<b>Table 21:</b>	Correlation between sex, Ca, LDH, Creat., bone lytic lesions, hemoglobin, stage and vitamin D level .....	80

# List of Figures

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Approach to the treatment of newly diagnosed multiple myeloma in transplant eligible (A) and transplant ineligible (B) patients. ....	33
<b>Figure (2):</b>	Comparison between post therapy group and newly diagnosed group regarding bone marrow.....	70
<b>Figure (3):</b>	Comparison between post therapy group and newly diagnosed group regarding Hb. ....	71
<b>Figure (4):</b>	Comparison between the three groups regarding vitamin D level.....	73
<b>Figure (5):</b>	Correlation between vitamin D level and creat. ....	81

# List of Abbreviations

Abb.	Full term
<i>AL</i> .....	<i>Light chain amyloidosis</i>
<i>ASCT</i> .....	<i>Autologous stem cell transplantation</i>
<i>BMI</i> .....	<i>Body mass index</i>
<i>CA</i> .....	<i>Chromosomal abnormalities</i>
<i>CCyD</i> .....	<i>Carfilzomib-Cyclophosphamide-Dexamethasone</i>
<i>CR</i> .....	<i>Complete response</i>
<i>CTCL</i> .....	<i>Cutaneous T-cell leukemia</i>
<i>CVD</i> .....	<i>Cardiovascular disease</i>
<i>DLBCL</i> .....	<i>Diffuse large B-cell lymphoma</i>
<i>D-S</i> .....	<i>Durie-Salmon staging system</i>
<i>ENKTL</i> .....	<i>Extranodal natural killer/T - cell lymphoma</i>
<i>FCM</i> .....	<i>Flowcytometry</i>
<i>GN</i> .....	<i>Glomerulonephritis</i>
<i>iFISH</i> .....	<i>Interphase fluorescent in situ hybridization</i>
<i>IOM</i> .....	<i>Institute of Medicine</i>
<i>ISS</i> .....	<i>International Staging System</i>
<i>KPD</i> .....	<i>Carfilzomib, pomalidomide, dexamethasone</i>
<i>KRD</i> .....	<i>Carfilzomib-Lenalidomide-Dexamethasone</i>
<i>LHCs</i> .....	<i>Lymphohematopoietic cancers</i>
<i>MF</i> .....	<i>Mycosis fungoides</i>
<i>MGUS</i> .....	<i>Monoclonal gammopathy of unknown significance</i>
<i>MIDD</i> .....	<i>Monoclonal Ig deposition disease</i>
<i>MM</i> .....	<i>Multiple myeloma</i>
<i>MP</i> .....	<i>Melphalan-Prednisone</i>
<i>MPT</i> .....	<i>Melphalan-Prednisone-Thalidomide</i>

## List of Abbreviations cont...

Abb.	Full term
<i>MR</i> .....	<i>Minor response</i>
<i>MRD</i> .....	<i>Minimal residual disease</i>
<i>mSMART</i> .....	<i>Mayo Stratification of Myeloma and Risk-Adapted Therapy</i>
<i>NGF</i> .....	<i>Next-generation flow cytometry</i>
<i>NGS</i> .....	<i>Next-generation sequencing</i>
<i>NHL</i> .....	<i>Non-Hodgkin's lymphoma</i>
<i>NK</i> .....	<i>Natural killer</i>
<i>NNR</i> .....	<i>Nordic Nutrition Recommendations</i>
<i>OS</i> .....	<i>Overall survival</i>
<i>PCP</i> .....	<i>Pomalidomide, cyclophosphamide, prednisone</i>
<i>PD</i> .....	<i>Progressive disease</i>
<i>PET-CT</i> .....	<i>Positron emission tomography-computed tomography</i>
<i>Pom / Dex</i> .....	<i>Pomalidomide-Dexamethasone</i>
<i>PR</i> .....	<i>Partial response</i>
<i>PTG</i> .....	<i>Parathyroid gland</i>
<i>PVD</i> .....	<i>Pomalidomide, bortezomib, dexamethasone</i>
<i>Rd</i> .....	<i>Lenalidomide-Dexamethasone</i>
<i>RFS</i> .....	<i>Relapse free survival</i>
<i>R-ISS</i> .....	<i>Revised-International Staging System</i>
<i>sCR</i> .....	<i>Stringent complete response</i>
<i>SD</i> .....	<i>Stable disease</i>
<i>SLAMF7</i> .....	<i>Signaling lymphocytic activation molecule F7</i>
<i>SMM</i> .....	<i>Smoldering MM</i>
<i>SREs</i> .....	<i>Skeleton-related events</i>

## List of Abbreviations cont...

Abb.	Full term
<i>SS</i> .....	<i>Sézary syndrome</i>
<i>TD</i> .....	<i>Thalidomide-Dexamethasone</i>
<i>TMA</i> .....	<i>Thrombotic microangiopathy</i>
<i>TTT</i> .....	<i>Time-to-treatment</i>
<i>VCD or CyBorD</i> .....	<i>Bortezomib-Cyclophosphamide-Dexamethasone</i>
<i>VD</i> .....	<i>Bortezomib-Dex</i>
<i>VDR</i> .....	<i>Vitamin D receptor</i>
<i>VDT-PACE</i> .....	<i>Bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide</i>
<i>VGPR</i> .....	<i>Very good partial response</i>
<i>VMP</i> .....	<i>Bortezomib-Melphalan-Prednisone</i>
<i>VRD</i> .....	<i>Bortezomib-Lenalidomide-Dexamethasone</i>
<i>VTD</i> .....	<i>Bortezomib-Thalidomide-Dexamethasone</i>
<i>WHO</i> .....	<i>World Health Organization</i>

## INTRODUCTION

Vitamin D (D represents D<sub>2</sub>, D<sub>3</sub>, or both) is a secosterol produced endogenously in the skin from sun exposure or obtained from foods that naturally contain vitamin D, including cod liver oil and fatty fish (eg, salmon, mackerel, and tuna); UV-irradiated mushrooms; foods fortified with vitamin D; and supplements (*Hosseini-nezhad et al., 2012*). So, Vitamin D levels can be significantly affected by skin pigmentation, sun-protection habits, geographic residency and diet. No seasonal variation in vitamin D status was noted (*Ng et al., 2009*).

1,25(OH)<sub>2</sub>D<sub>3</sub>, the hormonal derivative of vitamin D exerts its growth-regulatory effect through binding to the intranuclear receptor vitamin D receptor (VDR) (*Baker et al., 1988*).

Vitamin D deficiency is the most common nutritional deficiency worldwide (*Maier et al., 2013*). As yet there is no universally accepted classification of vitamin D levels, sufficient vitamin D status is defined as a serum 25-OH-D level of above 30 ng/ml. Vitamin D inadequacy is defined as serum 25-OH-D level under 30 ng/ml and further divided into vitamin D insufficiency (10 to 30 ng/ml) and vitamin D deficiency (under 10 ng/ml) (*Gallagher et al., 2010*).

Moderate vitamin D deficiency can cause a decrease in intestinal calcium absorption and an increase in PTH. PTH activates osteoblasts, which stimulate the transformation of

preosteoclasts into mature osteoclasts. These cells dissolve the mineralised collagen matrix in bone, causing osteoporosis and increase fracture risk (*Souberbielle et al., 2006*).

Several studies have begun to examine the relationship between circulating vitamin D levels and hematologic malignancies; Vitamin D insufficiency is associated with inferior time-to-treatment and Overall survival in chronic lymphocytic leukemia patients (*Shanafelt et al., 2011*), also there is a significant decrease in non-Hodgkin lymphoma risk with increased sun exposure (*Kelly et al., 2012*), vitamin D insufficiency in follicular lymphoma (FL) is predictive of early clinical failure among all patients (*Tracy et al., 2017*), the pretreatment serum 25(OH)D level was higher in patients with the indolent type of lymphoproliferative disease, CLL, than in patients with DLBCL, FL, and HL (*Djurasinović et al., 2018*).

Multiple myeloma (MM) accounts for 1.6% of all cancers and 5% to 10% of all hematologic malignancies (*Anwer et al., 2018*). It is considered a treatable but incurable disease, and thus lifelong observation and follow- up are recommended (*Anderson et al, 2016*).

International Myeloma Working Group updated indications to start treatment in MM patients. Some laboratory and radiographic variables are added to existing CRAB features. These features include bone marrow plasma cells  $\geq 60\%$ , abnormal MRI with more than one focal lesion, with

each lesion  $>5$  mm, and involved/uninvolved serum free light chain ratio  $\geq 100$  (*Rajkumar, 2016*).

Osteolytic lesions develop in nearly 90% of patients with MM, and these are frequently complicated by skeleton-related events (SREs) such as severe bone pain, pathologic fractures, vertebral collapse, hypercalcemia, and spinal cord compression (*O'Donnell and Raje, 2017*); It is estimated that 20% of MM patients present with pathologic fractures, 40% develop a fracture in the first year after diagnosis, and up to 60% develop pathologic fractures over the course of their disease) (*Melton et al., 2005*).

Vitamin D deficiency is extremely common in multiple myeloma, with 40% of patients having vitamin D levels in the deficient range of levels less than 36 nmol/L and it represents a surrogate feature for clinical multiple myeloma disease status (*Diamond et al., 2010*).

It has a significant clinical role in MM patients because of their interrelationship with calcium homeostasis and bone metabolism (*Holick, 2007*).

The prevalence of vitamin D deficiency increased in parallel with International Staging System (ISS) (*Greipp et al., 2005*); 16% of patients in Stage I, 20% in Stage II, and 37% in Stage III (*Ng et al., 2009*).

## **AIM OF THE WORK**

**T**he aim of the present study is to compare between vitamin D level in newly diagnosed patients with Multiple Myeloma and patients in remission.

## Chapter 1:

# MULTIPLE MYELOMA

### Definition:

**M**ultiple myeloma is characterized by the uncontrolled proliferation of monoclonal plasma cells in the bone marrow, leading to production of nonfunctional intact immunoglobulins or immunoglobulin chains (*Swerdlow et al, 2011*).

It is considered a treatable but incurable disease, and thus lifelong observation and follow-up are recommended (*Anderson et al, 2016*).

Plasma cell dyscrasias encompass a spectrum of disease which include asymptomatic premalignant proliferation of plasma cells (monoclonal gammopathy of unknown significance [MGUS]) and asymptomatic MM (smoldering MM (SMM)) to malignant disease (MM and plasma cell leukemia) with end-organ damage and associated significant patient morbidity (*Landgren, 2013*).

### Incidence:

Multiple myeloma (MM) is the second most commonly diagnosed hematological neoplasm, with an incidence rate of 6.2 per 100 000 individuals (*Seigel et al, 2016*).